Skip to main content
SEND FEEDBACK
Clinical Trial
Study Details
Status
RECRUITING
Study ID #
NCT06465810
Study Start
Primary Completion
Study Completion
Enrollment
1850
Study Type
Observational
Summary

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.

Description

MaesTTRo is an international, longitudinal, non-interventional study of adult patients with transthyretin (ATTR) amyloidosis.

The study plans to enroll a minimum of 1850 patients with ATTR amyloidosis, including a minimum of 850 patients with ATTR cardiomyopathy (ATTR-CM), and a minimum of 100 patients with ATTRv-PN hereditary polyneuropathy.

The enrollment period is expected to last approximately 4 years. The duration of follow-up for each patient will be at least 3 years and up to 7 years depending on the date when the patient is enrolled.

This study design will include both primary and secondary data. Primary data will consist of patient-reported outcome (PRO) questionnaires. Patients will be asked to complete electronic PRO questionnaires at enrollment and every 6 months (±3 months) only during routine visits. Secondary data will consist of demographic, clinical, and treatment information, and will be collected as per routine clinical practice. These data will be abstracted directly from the electronic health record or review of paper charts for each patient and entered in the electronic data capture system. No site visits are required for this study, and patients will not be contacted for data collection outside of routine clinic visits.

For patients enrolled in the United States, a tokenization process (creation of a unique, encrypted identifier called a token, in place of personal identifiable information) will be used to collect additional de-identified data (e.g., healthcare resource use, healthcare costs) from other sources that are part of patients' routine medical care (electronic medical, hospital, or pharmacy records). Only de-identified data will be analyzed. Patients will be given a choice within the informed consent form to opt in or opt out of participating in the tokenization process.

Conditions
Transthyretin Amyloidosis
ATTR-CM
ATTRv-PN
ATTR
ATTR-Mixed
hATTR
Study Contact
Name
AstraZeneca Clinical Study Information Center
Role
Contact
Phone
1-877-240-9479
Email
information.center@astrazeneca.com
Locations
Facility

Research Site
La Jolla, California 92037
United States

Facility

Research Site
Los Angeles, California 90095
United States

Facility

Research Site
San Francisco, California 94025
United States

Facility

Research Site
San Francisco, California 94143
United States

Facility

Research Site
New Haven, Connecticut 006510
United States

Facility

Research Site
Washington D.C., District of Columbia 20010
United States

Facility

Research Site
Chicago, Illinois 60637
United States

Facility

Research Site
Indianapolis, Indiana 06200
United States

Facility

Research Site
Baltimore, Maryland 21218
United States

Facility

Research Site
Boston, Massachusetts 02111
United States

Facility

Research Site
Boston, Massachusetts 02114
United States

Facility

Research Site
Boston, Massachusetts 02115
United States

Facility

Research Site
Rochester, Minnesota 55905
United States

Facility

Research Site
Kansas City, Missouri 64111
United States

Facility

Research Site
St Louis, Missouri 63110
United States

Facility

Research Site
New Brunswick, New Jersey 08901
United States

Facility

Research Site
Manhasset, New York 11030
United States

Facility

Research Site
New York, New York 10016
United States

Facility

Research Site
New York, New York 10027
United States

Facility

Research Site
New York, New York 10029
United States

Facility

Research Site
Durham, North Carolina 27710
United States

Facility

Research Site
Portland, Oregon 97239
United States

Facility

Research Site
Danville, Pennsylvania 17822
United States

Facility

Research Site
Philadelphia, Pennsylvania 19104
United States

Facility

Research Site
Philadelphia, Pennsylvania 19107
United States

Facility

Research Site
Greenville, South Carolina 29607
United States

Facility

Research Site
Germantown, Tennessee 38138
United States

Facility

Research Site
Nashville, Tennessee 037214
United States

Facility

Research Site
Dallas, Texas 75246
United States

Facility

Research Site
Houston, Texas 77030
United States

Facility

Research Site
Richmond, Virginia 23298
United States

Facility

Research Site
Seattle, Washington 98915
United States

Facility

Research Site
Milwaukee, Wisconsin 53226
United States

Facility

Research Site
Vancouver British Columbia V5Z 1M9
Canada

Facility

Research Site
Vancouver British Columbia V6Z 1Y6
Canada

Facility

Research Site
Halifax Nova Scotia B3RIV9
Canada

Facility

Research Site
London Ontario N6A 5A5
Canada

Facility

Research Site
Toronto Ontario M2J 4W8
Canada

Facility

Research Site
Montreal Quebec H2X 0A9
Canada

Facility

Research Site
Rimouski Quebec G5L 5T1
Canada

Facility

Research Site
Hefei
Anhui, 230001
China

Facility

Research Site
Beijing
Beijing Municipality, 100029
China

Facility

Research Site
Beijing
Beijing Municipality, 100034
China

Facility

Research Site
Beijing
Beijing Municipality, 100191
China

Facility

Research Site
Beijing
Beijing Municipality, 100730
China

Facility

Research Site
Chongqing
Chongqing Municipality, 400000
China

Facility

Research Site
Fuzhou
Fujian, 350005
China

Facility

Research Site
Xiamen
Fujian, 361016
China

Facility

Research Site
Guangzhou
Guangdong, 510080
China

Facility

Research Site
Guangzhou
Guangdong, 510515
China

Facility

Research Site
Guiyang
Guizhou, 550004
China

Facility

Research Site
Shijiazhuang
Hebei, 050000
China

Facility

Research Site
Wuhan
Hubei, 430000
China

Facility

Research Site
Wuhan
Hubei, 430030
China

Facility

Research Site
Changsha
Hunan, 410011
China

Facility

Research Site
Changsha
Hunan, 410013
China

Facility

Research Site
Nanjing
Jiangsu, 210029
China

Facility

Research Site
Suzhou
Jiangsu, 215006
China

Facility

Research Site
Nanchang
Jiangxi, 330000
China

Facility

Research Site
Dalian
Liaoning, 116011
China

Facility

Research Site
Jinan
Shandong, 250012
China

Facility

Research Site
Shanghai
Shanghai Municipality, 200025
China

Facility

Research Site
Shanghai
Shanghai Municipality, 200031
China

Facility

Research Site
Shanghai
Shanghai Municipality, 200040
China

Facility

Research Site
Taiyuan
Shanxi, 030001
China

Facility

Research Site
Chengdu
Sichuan, 610041
China

Facility

Research Site
Chengdu
Sichuan, 610072
China

Facility

Research Site
Shaanxi
Xi'An, 710061
China

Facility

Research Site
Hangzhou
Zhejiang, 310009
China

Facility

Research Site
DE-97072 Würzburg
Germany

Facility

Research Site
60590 Frankfurt am Main
Germany

Facility

Research Site
30625 Hanover
Germany

Facility

Research Site
52074 Aachen
Germany

Facility

Research Site
50937 Cologne
Germany

Facility

Research Site
55131 Mainz
Germany

Facility

Research Site
66421 Homburg
Germany

Facility

Research Site
10117 Berlin
Germany

Facility

Research Site
21005 Huelva Andalusia
Spain

Facility

Research Site
48013 Bilbao Basque Country
Spain

Facility

Research Site
35010 Las Palmas de Gran Canaria Canary Islands
Spain

Facility

Research Site
37007 Salamanca Castille and León
Spain

Facility

Research Site
08035 Barcelona Catalu A
Spain

Facility

Research Site
8036 Barcelona Catalu A
Spain

Facility

Research Site
08907 Cataluna Catalu A
Spain

Facility

Research Site
28222 Majadahonda Madrid
Spain

Facility

Research Site
07198 Islas Baleares Palma de Mallorca
Spain

Facility

Research Site
Birmingham
B15 2GW
United Kingdom

Facility

Research Site
Glasgow
G51 4TF
United Kingdom

Facility

Research Site
London
NW3 2QG
United Kingdom

Somebody To Talk To, Inc. is a CT nonprofit corporation operating through a fiscal sponsorship with Players Philanthropy Fund, a Maryland charitable trust recognized by IRS as a tax-exempt public charity under Section 501(c)(3) of the Internal Revenue Code (Federal Tax ID: 27-6601178). Contributions to Somebody To Talk To are tax-deductible to the fullest extent of the law. The information provided on this website is for educational and informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider regarding any medical conditions or treatment options.